NLM Digital Collections

Search

Start Over Subjects Prescription Drug Diversion ✖Remove constraint Subjects: Prescription Drug Diversion Dates by Range 2000 and later ✖Remove constraint Dates by Range: 2000 and later Publication Year 2017 to 2019 ✖Remove constraint Publication Year: <span class="from" data-blrl-begin="2017">2017</span> to <span class="to" data-blrl-end="2019">2019</span>

1. Drug supply chain security: wholesalers exchange most tracing information

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, September 2017
Subject(s):
Pharmaceutical Preparations -- supply & distribution
Prescription Drug Diversion
Information Dissemination
Security Measures
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

2. Drug supply chain security: dispensers received most tracing information

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, March 2018
Subject(s):
Pharmaceutical Preparations -- supply & distribution
Prescription Drug Diversion
Drug Industry
Information Dissemination
Pharmacies
Security Measures
Humans
United States
United States. Department of Health and Human Services.

3. Opioid use in Medicare Part D remains concerning

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, June 2018
Subject(s):
Analgesics, Opioid -- therapeutic use
Medicare Part D
Opioid-Related Disorders -- epidemiology
Prescription Drug Misuse
Analgesics, Opioid -- economics
Fentanyl -- adverse effects
Prescription Drug Diversion
Humans
United States
United States. Department of Health and Human Services.

4. Why health plans should go to the "MAT" in the fight against opioid addiction

Author(s):
Elitzer, Julia, author
Tatar, Margaret, author
Publication:
[Oakland, Calif.] : California Health Care Foundation, September 2017
Subject(s):
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Opioid-Related Disorders -- prevention & control
Buprenorphine -- therapeutic use
Comparative Effectiveness Research
Cost Savings
Drug Overdose -- drug therapy
Drug Overdose -- prevention & control
Health Care Costs
Health Services Accessibility
Healthcare Disparities
Inappropriate Prescribing -- prevention & control
Insurance Coverage -- legislation & jurisprudence
Managed Care Programs
Medicaid
Mental Health Services -- legislation & jurisprudence
Methadone -- therapeutic use
Naloxone
Naltrexone -- therapeutic use
Neonatal Abstinence Syndrome -- drug therapy
Opioid-Related Disorders -- epidemiology
Patient Care Management
Prescription Drug Diversion
State Government
Humans
California
United States

5. Enforcement and compliance

Author(s):
Berry, Melissa D., author
Publication:
[Toronto, Ontario] : Thomson Reuters, 23-December-2019
Subject(s):
Crime
Fraud -- prevention & control
Government Regulation
Health Care Reform -- legislation & jurisprudence
Conflict of Interest
Drug Industry -- legislation & jurisprudence
Electronic Health Records -- legislation & jurisprudence
Federal Government
Medicaid -- legislation & jurisprudence
Medicare -- legislation & jurisprudence
Opioid-Related Disorders
Prescription Drug Diversion
State Government
Telemedicine -- legislation & jurisprudence
Whistleblowing
Humans
United States
United States.
Centers for Medicare & Medicaid Services (U.S.)
State Children's Health Insurance Program (U.S.)

6. Business practices

Author(s):
Steiner, David J., author
Publication:
Toronto, Ontario : Thomson Reuters, 23-December-2019
Subject(s):
Commerce
Drug Industry -- legislation & jurisprudence
Equipment and Supplies
Legislation, Drug
Analgesics, Opioid
Crime
Equipment Failure
Equipment Safety
Federal Government
Fraud
Medical Device Recalls
Opioid-Related Disorders -- epidemiology
Patents as Topic
Prescription Drug Diversion
Humans
United States

8. Buprenorphine: an overview for clinicians

Author(s):
Steiger, Scott, author
DeFries, Triveni, author
Publication:
[Oakland, California] : California Health Care Foundation, August 2019
Subject(s):
Buprenorphine -- therapeutic use
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Ambulatory Care
Buprenorphine -- administration & dosage
Buprenorphine -- adverse effects
Drug and Narcotic Control
Emergency Service, Hospital
Health Services Accessibility
Mental Health Services
Methadone -- therapeutic use
Naltrexone -- therapeutic use
Pain -- drug therapy
Prescription Drug Diversion
Prisons
State Government
Telemedicine
Humans
California
United States